HQ Team
May 20, 2025: Regeneron Pharmaceuticals, Inc. plans to buy most of the assets of the bankrupt genetics and biotechnology company, 23andMe Holding, for $256 million.
The Tarrytown, New York-based company was named the successful bidder in the bankruptcy auction for substantially all of the assets of 23andMe Holding Co., according to a company statement.
Regeneron plans to acquire 23andMe’s Personal Genome Service, Total Health and Research Services business lines, together with its Biobank and associated assets.
23andMe will continue its consumer genome services uninterrupted. Subject to bankruptcy court and regulatory approvals and other customary closing conditions, the deal is expected to close in the third quarter of 2025.
Learning about one’s DNA
23andMe will be operated as a wholly owned direct or indirect subsidiary of Regeneron Pharmaceuticals, Inc. and continue operations as a personal genomics service.
Regeneron’s purchase does not include 23andMe’s Lemonaid Health business.
“Regeneron was one of the first biotech companies to bet its future on the power of DNA, fueling our drug discovery efforts to deliver some of the world’s leading and most innovative medicines, including treatments to prevent blindness, for allergic diseases from asthma to atopic dermatitis, for several forms of cancer, and even for Ebola and COVID-19,” said George D. Yancopoulos, co-Founder, President and Chief Scientific Officer of Regeneron.
“We believe we can help 23andMe deliver and build upon its mission to help those interested in learning about their DNA and how to improve their health, while furthering Regeneron’s efforts to use large-scale genetics research to improve the way society treats and prevents illness overall.”
Customer Privacy Ombudsman
Regeneron intends to ensure compliance with 23andMe’s consumer privacy policies and applicable laws concerning the treatment of customer data, he said.
As the successful bidder, Regeneron is prepared to detail the intended use of customer data and the privacy programs and security controls in place for review by a court-appointed, independent Customer Privacy Ombudsman and other interested parties, according to the statement.
“23andMe is a pioneer in consumer genetics and research, and we are excited for the opportunity to support their important mission and grow their platform and business,” said Aris Baras, MD, Senior Vice President and Head of the Regeneron Genetics Center.
“We assure 23andMe customers that we are committed to protecting the 23andMe dataset with our high standards of data privacy, security and ethical oversight and will advance its full potential to improve human health.”
Since 2013, the Regeneron Genetics Center has sequenced the genetic information of nearly three million people in research studies, using this de-identified data to make meaningful discoveries at speed and scale, he said.
